Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Wei-Li Ma, Wang-Da Liu, Hsin-Yun Sun, Wang-Huei Sheng, Szu-Min Hsieh, Shang-Ju Wu, Chien-Ching Hung
BACKGROUND: The prognosis for people living with HIV (PLWH) who develop lymphomas has been greatly improved by combination antiretroviral therapy (cART) and anti-CD20 monoclonal antibodies. However, real-world clinical data on this patient group in Asia are limited. METHODS: Treatment outcomes were retrospectively examined for 104 PLWH with lymphomas between 2000 and 2019. The cohort comprised five PLWH with Hodgkin lymphoma (HL) and 99 with non-Hodgkin lymphomas, including 61 with diffuse large B-cell lymphoma (DLBCL), 19 with Burkitt lymphoma (BL), nine with primary central nervous system lymphoma (PCNSL) and ten with other subtypes...
April 6, 2024: Journal of Microbiology Immunology and Infection
#2
JOURNAL ARTICLE
Lina Martina Würfel, Anja Potthoff, Sandeep Nambiar, Adriane Skaletz-Rorowski
BACKGROUND: HIV testing remains an important tool in identifying people living with HIV/AIDS (PLWHA). An early diagnosis of HIV can lead to a prolonged life expectancy if treatment is initiated promptly. Indicator conditions can be the first sign of an HIV infection and should therefore be recognised and consequently a HIV test should be carried out. Testing should occur in all individuals as sexuality can be experienced by everyone, and stigma can lead to the exclusion of vulnerable groups, leading to a gap in diagnosis and treatment [1, 2]...
April 5, 2024: AIDS Research and Therapy
#3
REVIEW
Jan Vesterbacka, Anna-Karin Svensson, Piotr Nowak
Sweden is a country with a low prevalence of human lymphotropic T-cell virus (HTLV) infection, estimated at < 0.005%, but the infection rate is notably higher in specific risk groups such as HTLV-2 among intravenous drug users (IVDU) and people originating from HTLV-1 highly endemic areas. Thus, in the most recent study from 2012, the prevalence of HTLV-2 among IVDU in Stockholm was 3.2%. However, much of the epidemiological data on HTLV in Sweden stems from studies conducted primarily between the 1990s and 2007, and the impact of migration to Sweden during the past 15 years has not been evaluated...
2024: AIDS Reviews
#4
JOURNAL ARTICLE
Sarah May Johnson, Jhia Jiat Teh, Thomas Joshua Pasvol, Sara Ayres, Hermione Lyall, Sarah Fidler, Caroline Foster
INTRODUCTION: Complex challenges amongst ageing cohorts of adolescents and adults living with perinatally acquired HIV (PaHIV) may impact on hospitalisation. We report hospitalisation rates and explored predictive factors for hospitalisation in adolescents and adults (10-35 years) living with PaHIV in England. METHOD: Retrospective observational cohort study over a three-year period 2016-2019. Data collected included cause and duration of hospitalisation, HIV viral load and CD4 lymphocyte count...
2024: PloS One
#5
JOURNAL ARTICLE
Juanjuan Chen, Yihua Wu, Han Zhao, Guangjing Ruan, Shanfang Qin
BACKGROUND: Despite the introduction of combined antiretroviral therapy, AIDS-related diffuse large B-cell lymphoma (AR-DLBCL) remains a prominent cancer among individuals living with HIV with a suboptimal prognosis. Identifying independent prognostic markers could improve risk stratification. METHODS: In this multicenter retrospective cohort study spanning years 2011 to 2019, 153 eligible patients with AR-DLBCL were examined. Overall survival (OS) factors were analyzed using Kaplan-Meier curves, and univariate and multivariate Cox proportional hazards models...
2024: Frontiers in Immunology
#6
JOURNAL ARTICLE
Chia-Shang Wu, Yu-Ching Wen, Wei-Yu Chen, Tzeon-Jye Chiou
The Epstein-Barr virus-associated smooth muscle tumor (SMT) is an uncommon neoplasm. It arises mainly in 3 immunosuppression settings: HIV-associated SMT; drug-related immunosuppression in transplant recipients; and congenital immunodeficiency disorder-associated SMT. We present 18F-FDG PET/CT findings of an adrenal Epstein-Barr virus-associated SMT in a 65-year-old woman with a history of follicular lymphoma after chemotherapy.
February 27, 2024: Clinical Nuclear Medicine
#7
JOURNAL ARTICLE
Manimaran Ramyasri, Vikram Singh, Natarajan Mohan Rangan, Indranil Deb Roy, Kapil Tomar, Ajay P Desai, Rekha Yadav, Mukesh Krishnan
Plasmablastic lymphoma (PBL) is an uncommon and aggressive large B-cell lymphoma commonly diagnosed in human immunodeficiency virus-positive patients. Though the oral cavity is a common site for PBL, this condition is not commonly reported in the literature as an oral manifestation. Most oral PBLs presented as an asymptomatic swelling, frequently associated with ulcerations and bleeding. No standard treatment is yet advocated for oral PBL. Five-year survival rate was recorded not more than 33.5%. This presentation emphasizes on oral manifestation of plasmablastic lymphoma (PBL) as a rare entity, which was provisionally diagnosed for carcinoma (CA) oral cavity...
February 16, 2024: Journal of Craniofacial Surgery
#8
JOURNAL ARTICLE
Marriam Mponda, Evaristar Kudowa, Dalton M Craven, Luke C Eastburg, Maria Chikasema, Edwards Kasonkanji, Tamiwe Tomoka, Sophie Maharry Roush, Lusayo Simwinga, Noel Mumba, Satish Gopal, Yuri Fedoriw, Matthew S Painschab
BACKGROUND: ABVD (doxorubicin, bleomycin, vinblastine, and dexamethasone) is a proven, curative regimen for Hodgkin lymphoma (HL). Prospective data describing HL treatment in sub-Saharan Africa are limited. We aimed to fill this knowledge gap, using data from Malawi. METHODS: We report a prospective observational cohort of HL (aged <mml:math xmlns:mml="https://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mo>≥</mml:mo></mml:mrow></mml:math> 15) from a single, tertiary referral centre in Malawi...
March 2024: EClinicalMedicine
#9
JOURNAL ARTICLE
Anna Shmakova, Coline Hugot, Yana Kozhevnikova, Anna Schwager Karpukhina, Ivan Tsimailo, Laurence Gérard, David Boutboul, Eric Oksenhendler, Olga Szewczyk-Roszczenko, Piotr Roszczenko, Kamila Buzun, Eugene V Sheval, Diego Germini, Yegor Vassetzky
Despite the success of combination antiretroviral therapy, people living with human immunodeficiency virus (HIV) still have an increased risk of Epstein-Barr virus (EBV)-associated B cell malignancies. In the HIV setting, B cell physiology is altered by coexistence with HIV-infected cells and the chronic action of secreted viral proteins, for example, HIV-1 Tat that, once released, efficiently penetrates noninfected cells. We modeled the chronic action of HIV-1 Tat on B cells by ectopically expressing Tat or TatC22G mutant in two lymphoblastoid B cell lines...
February 2024: Journal of Medical Virology
#10
Nilton José da Silva Filho, Diovana de Melo Cardoso, Giseli Mitsuy Kayahara, José Cândido Caldeira Xavier-Júnior, Gabriel Macedo Cortopassi, Felipe Paiva Fonseca, Glauco Issamu Miyahara, Daniel Galera Bernabé, Vitor Bonetti Valente
BACKGROUND: Burkitt lymphoma (BL) is a subtype of non-Hodgkin lymphoma. It is strongly associated with HIV infection and has a highly aggressive clinical course. The involvement of the maxillofacial region in BL has rarely been reported. CASE DESCRIPTION: A 36-year-old woman with HIV-positive status had painless bilateral swelling of the oral mucosa and middle and lower thirds of the face. Microscopic analysis of the oral lesion revealed an atypical lymphoid infiltrate with a starry sky pattern...
January 20, 2024: Journal of the American Dental Association
#11
JOURNAL ARTICLE
Camila Alves, Juliana Pereira, Eduardo M Rego, Vanderson Rocha, Wellington F Silva
INTRODUCTION: High-dose methotrexate (HDMTX) is an essential part of chemotherapy regimens for hematologic neoplasms. The incidence of acute kidney injury (AKI) after HDMTX in unmonitored outpatient infusion had not been reported in adults yet. In this study, we evaluated toxicity data after outpatient administration of HDMTX without drug monitoring. METHODS: Patients 16 years old or over with acute lymphoblastic leukemia and non-Hodgkin lymphoma who received at least one outpatient infusion of HDMTX without drug level monitoring were included...
December 19, 2023: Hematology, Transfusion and Cell Therapy
#12
JOURNAL ARTICLE
Melanie Lopez, Radhika Kainthla, Susana Lazarte, Weina Chen, Ank E Nijhawan, Sheena Knights
OBJECTIVE: To describe cases of Kaposi's sarcoma-associated herpesvirus (KSHV)-associated multicentric Castleman's disease (MCD) and primary effusion lymphoma (PEL) in patients with HIV from a large, safety-net hospital system in Dallas, Texas, USA. METHODS: We conducted a retrospective review of patients with HIV-associated PEL and/or MCD. RESULTS: Twelve patients with PEL and 10 patients with MCD were identified. All patients were male and 17 of 20 were men who have sex with men; 66...
December 28, 2023: European Journal of Haematology
#13
JOURNAL ARTICLE
Mohamed Abdel-Samiee, Mohamed I Youssef, Fathy Elghamry, Mahmoud Bazeed, Mohamed Al-Shorbagy, Helmy Shalaby, Hossam Shabana, Eman Abdelsameea, Hesham El Sayed Lashin, Hossam M Farid El Zamek, Tarek Esam, Mohammad AbdElhameed Ahmed Alwaseef, Housam Ahmed Helmy, Feras Almarshad, Fatma A Khalaf, Badawy W AboBakr Yossef, Arafat Kassem, Basant Mostafa Gabr, Ahmed Abdelfattah, Hind S AboShabaan, Galal Abdelhameed Aboufarrag, Marwa M Omar, Mohammed Saied Bakeer, Mohammed S Imam, Essam S Ibrahim, Shimaa Y Kamel, Talaat Allisy, Omima Sayed Mohammed, Ali Farahat, Mohsen M El-Khayat, Mohamed Abdelrafaa Hassan Sekeen, Eman Mohammed Zaher, Ashraf Said, Ahmed Abuamer, Essam Elmahdi
The infection caused by the hepatitis C virus (HCV) is a significant global health concern. The prevailing genotype of HCV in Egypt is 4a, commonly referred to as GT-4a. A significant proportion exceeding 50% of patients infected with HCV experience extrahepatic manifestations (EHMs), encompassing a diverse range of clinical presentations. These manifestations, including essential mixed cryoglobulinemia (MC), can serve as initial and solitary indicators of the disease. The complete understanding of the pathogenesis of EHM remains unclear, with autoimmune phenomena being recognized as the primary causative factor...
December 2023: Journal of Medical Virology
#14
JOURNAL ARTICLE
I Suárez-García, Félix Gutierrez, José A Pérez-Molina, Santiago Moreno, Teresa Aldamiz, Eulalia Valencia Ortega, Adrián Curran, Sara Gutiérrez González, Víctor Asensi, Concha Amador Prous, Inma Jarrin, Marta Rava
PURPOSE: Our aim was to describe non-AIDS-defining cancer (NADC) mortality among people living with HIV (PLWH), to compare it with that of the general population, and to assess potential risk factors. METHODS: We included antiretroviral-naive PLWH from the multicentre CoRIS cohort (2004-2021). We estimated mortality rates and standardised mortality ratios (SMRs). We used cause-specific Cox models to identify risk factors. RESULTS: Among 17,978 PLWH, NADC caused 21% of all deaths observed during the follow-up...
November 26, 2023: Journal of Cancer Research and Clinical Oncology
#15
REVIEW
Christopher R D'Angelo
Primary CNS lymphoma (PCNSL) is a rare lymphoma representing 3% of CNS malignancies. The diagnosis is complicated by the unique risks associated with brain biopsy, and the treatment is similarly complicated by the restriction of effective therapeutics able to cross the blood-brain barrier. Currently, the majority of individuals diagnosed with this disease are immunocompetent although immune deficiency related to HIV or immunosuppressive therapy remains an important risk factor. Improvements in both frontline therapy and consolidation options, including the use of hematopoietic stem-cell transplantation, have translated to improved survival...
November 15, 2023: JCO oncology practice
#16
JOURNAL ARTICLE
Zhenyan Wang, Jingna Xun, Zichen Song, Yinzhong Shen, Li Liu, Jun Chen, Tangkai Qi, Jianjun Sun, Wei Song, Yang Tang, Shuibao Xu, Junyang Yang, Bihe Zhao, Renfang Zhang
No abstract text is available yet for this article.
November 3, 2023: Chinese Medical Journal
#17
RANDOMIZED CONTROLLED TRIAL
Martine E D Chamuleau, Frank Stenner, Dana A Chitu, Urban Novak, Monique C Minnema, Paul Geerts, Wendy B C Stevens, Thorsten Zenz, Gustaaf W van Imhoff, Ka Lung Wu, Astrid M P Demandt, Marie Jose Kersten, Wim E Terpstra, Lidwine W Tick, Dries Deeren, Eric Van Den Neste, Michael Gregor, Hendrik Veelken, Lara H Böhmer, Clemens B Caspar, Pim Mutsaers, Jeannine M Refos, Robby Sewsaran, Liping Fu, Rianne L Seefat, Carin A Uyl-de Groot, Stefan Dirnhofer, Michiel Van Den Brand, Daphne de Jong, Marcel Nijland, Pieternella Lugtenburg
BACKGROUND: Patients with newly diagnosed high-risk Burkitt lymphoma are treated with high-intensity immune-chemotherapy regimens such as R-CODOX-M/R-IVAC or with lower-intensity regimens such as DA-EPOCH-R. The aim of this study was to make a formal comparison between these regimens. METHODS: This multicentre, phase 3, open-label, randomised study was done in 26 clinical centres in the Netherlands, Belgium, and Switzerland. Eligible patients were aged 18-75 years with newly diagnosed high-risk Burkitt lymphoma without CNS involvement...
December 2023: Lancet Haematology
#18
JOURNAL ARTICLE
Ahmed Salem, Elizabeth M La, Desmond Curran, Brandon J Patterson, Justin Carrico, Stéphane Lorenc, Katherine A Hicks, Sara Poston, Christopher F Carpenter
INTRODUCTION: Immunocompromised (IC) adults are at increased risk of developing herpes zoster (HZ) and HZ-related complications due to therapy or underlying disease. This study evaluated the cost effectiveness of recombinant zoster vaccine (RZV) versus no vaccine for the prevention of HZ in hematopoietic stem cell transplant (HSCT) recipients and other IC adults aged ≥ 18 years in the United States (US). METHODS: A static Markov model simulated cohorts of IC individuals using a 1-year cycle length and 30-year time horizon to estimate the cost effectiveness of RZV...
November 2, 2023: PharmacoEconomics Open
#19
JOURNAL ARTICLE
Marie-Josephe Horner, Meredith S Shiels, Timothy S McNeel, Analise Monterosso, Paige Miller, Ruth M Pfeiffer, Eric A Engels
BACKGROUND: Combination antiretroviral therapy (cART) may reduce cancer risk among people with HIV (PWH), but cancer-specific associations are incompletely understood. METHODS: We linked HIV and cancer registries in Texas to a national prescription claims database. cART use was quantified as the proportion of days covered (PDC). Cox proportional hazards models assessed associations of cancer risk with cART usage, adjusting for demographic characteristics, AIDS status, and time since HIV report...
March 1, 2024: AIDS
#20
JOURNAL ARTICLE
Rolando Herrero, Loretto J Carvajal, M Constanza Camargo, Arnoldo Riquelme, Carolina Porras, Ana Patricia Ortiz, Luis Aranha Camargo, Valeria Fink, Vanessa van De Wyngard, Eduardo Lazcano-Ponce, Carlos Canelo-Aybar, Graciela Balbin-Ramon, Ariadna Feliu, Carolina Espina
About 13% of all cancers around the world are associated with infectious agents, particularly in low-resource settings. The main infectious agents associated with cancer are Helicobacter pylori (H. pylori), that causes gastric cancer, human papillomavirus (HPV) that causes cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancer, hepatitis B and C viruses that cause liver cancer, and human immunodeficiency virus (HIV), associated with cancers of the cervix, Kaposi sarcoma (KS) and non-Hodgkin´s lymphoma...
October 2023: Cancer Epidemiology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
